Boehringer, Zomedica team up on point-of-care PPID testing

Zomedica and Boehringer Ingelheim Animal Health USA have launched a strategic collaboration to fold Zomedica’s TRUFORMA point-of-care platform into Boehringer’s idPPID awareness and testing program for horses with suspected pituitary pars intermedia dysfunction, or PPID. The arrangement lets participating veterinarians run Zomedica’s equine endogenous ACTH and equine insulin assays in clinic, rather than relying only on reference-lab workflows, while Boehringer expands its program to reimburse testing performed on TRUFORMA as well as laboratory testing through Cornell University. The announcement was published March 24, 2026, and builds on Boehringer’s long-running PPID testing initiative, which has operated with Cornell since 2013 and has tested more than 50,000 horses. (equimanagement.com)

Why it matters: For equine veterinarians, the collaboration is really about speed, workflow, and case management. ACTH testing remains central to PPID diagnosis, but traditional testing can require careful sample handling, rapid plasma separation, and chilled shipment to an outside lab. Early data presented by University of Georgia researcher Kelsey Hart, DVM, PhD, DACVIM, found good overall agreement between TRUFORMA’s point-of-care eACTH assay and a chemiluminescent immunoassay, though bias was greater in PPID horses and some discrepant results could affect diagnosis. That means faster in-clinic answers may help practices triage and monitor horses sooner, but veterinarians will still need to interpret results carefully, especially in borderline or complex cases. (equimanagement.com)

What to watch: Watch for details on how broadly veterinarians enroll in the reimbursed program, whether TRUFORMA placement accelerates in equine practice, and whether additional validation data, especially in fall testing and clinically ambiguous cases, strengthen confidence in point-of-care PPID workflows. (equimanagement.com)